Abstract
The treatment of bladder cancer is very similar in Western Europe and the United States. Nevertheless, certain differences in treatment approach can be identified between countries. Within Europe, the preferred specific treatment protocols in France, Spain, and other south European countries are somewhat different from those in the north European countries such as the United Kingdom, Germany, the Benelux countries, and the Scandinavian countries. Comparing European countries and the United States, on the other hand, there are certain differences in attitude toward the use of surgical techniques and radiation therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beer M, Jocham D, Beer A, Staehler G (1989) Adjuvant laser treatment of bladder cancer: 8 years’ experience with the ND-YAG laser 1064 NM. Br J Urol 63: 476–478
Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153: 934–941
Bricker EM (1950) Bladder substitution after pelvic evisceration. Surg Clin North Am 30: 1511
Catalona WJ (1992) Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds) Campbell’s urology, 6th edn. Saunders, Philadelphia, pp 1094–1158
Crawford ED, Das S, Smith JA (1987) Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am 14: 781
D’Hallewin MA, Baert L (1995) Long term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. Urology 45: 763–767
Duncan W, Quilty PM (1986) The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 7: 299–310
Dunst J, Sauer R, Schrott KM, Kühn R, Wittekind C, Altendorf-Hofmann AA (1994) Organ-sparing treatment of advanced bladder carcinoma: a 10-year experience. Int J Radiat Oncol Biol Phys 30: 261–266
Fisch M, Wammack R, Steinbach F, Muller SC, Hohenfellner R (1993) Sigma-rectum pouch ( Mainz pouch II ). Urol Clin North Am 20: 561–569
Gospodarowicz MK, Quilty PM, Scalliet P, et al. (1995) The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 2 (Suppl 2): 41–48
Hautmann RE (1991) The ileal neobladder. Acta Urol Belg 59: 227–240
Huland H, Klöppel G, Otto U, et al. (1990) Comparison of different schedules of cytostatic intravesical installations in patients with superficial bladder carcinoma. First evaluation of a prospective multicenter study with 419 patients. J Urol 144: 68
Huland H, Otto U, Droese M, Klöppel G (1984) Long-term mitomycin installation after transurethral resection of superficial bladder carcinoma: influence of recurrence, progression and survival. J Urol 132: 27–33
Jahnson S, Pedersen J, Westman G (1991) Bladder carcinoma - a 20-year review of radical irradiation therapy. Radiother Oncol 22: 111–117
Jakse G, Frommhold H (1988) Radiotherapy and chemothe- rapy in locally advanced bladder cancer. Eur Urol 14: 45
Kaufaman DS, Shipley WU, Heney NM, et al. (1991) The integration of transurethral surgery, chemotherapy and radiation with bladder sparing in patients with invasive bladder cancer: an update of prognostic factors in a prospective trial (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 10: A516
Kock NG, Ghoneim MA, Lycke KG (1988) Urinary diversion to the augmented and valved rectum: preliminary results with a novel surgical procedure. J Urol 140: 1375
Koiso K, Shipley W, Keuppens F, et al (1995) The status of bladder-preserving therapeutic strategies in the manag-ment of patients with muscle-invasive bladder cancer. Int J Urol 2 (Suppl 2): 49–57
Kriegmair M, Waidelich R, Baumgartner R, Lumper W, Ehsan A, Hofstetter A (1994) (Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?) Die photodynamische Therapie ( PDT) des oberflachlichen Harnblasenkarzinoms. Eine Alternative zur radikalen Zystektomie? Urologe [A] 33: 276–280
Lample A, Hohenfellner M, Schultz-Lampel D, Thuroff JW (1995) In situ tunneled bowel flap tubes: 2 new techniques of a continent outlet for Mainz pouch cutaneous diversion. J Urol 153: 308–315
Lukkarinen O, Paul C, Hellstrom, P, et al (1991) Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumors. Scand J Urol Nephrol 25: 25–28
Martinez-Pineiro JA, Gonzalez-Martin M, Arocena F, et al. (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153: 964–973
Medical Research Council Working Party on Urological Research (1994) The effect of intravesical thiotepa on tumor recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Councial randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Baladder Cancer. Br J Urol 73: 632–638
Moore MJ, O’Sullivan B, Tannock IF (1988) How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 1736: 1736–1745
Mori K, Lamm KL, Crawford DE (1988) A trial of bacillus Calmette-Guérin vs. adriamycin in superficial bladder cancer: a Southwest Oncology Group Study. Urol Int 41: 254
Mulders PF, Hoekstra WJ, Heybroek RP, Schapers ER, Verbeek AL, Oosterhof GO, Debruyne FM (1994) Prognosis and treatment of T1G3 bladder tumors. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group (see comments). Eur J Cancer 30A: 914–917
Newling D (1990) Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group. Br J Cancer 61: 497–499
Newling DW, Robinson MR, Smith PH, et al. (1995) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomized phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27: 110–116
Oosterlinck W, Kurth KH, Schrodr F, Sylvester R, Hammond B (1993) A plea for cold biopsy, fulguration and immediate bladder instillation with epirubicin in small superficial bladder tumors. Data from the EORTC GU Group Stury 30863. Eur Urol 23: 457–459
Pavone-Macaluso M, Tripi M, Ingargiola GB, Corselli G, Pavone C, Serretta V (1993) Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin. J Chemother 5: 207–211
Prout GR Jr, Shipley WU, Kaufman DS, Giffin PP, Heney NM (1991) Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial. Urol Clin North Am 18: 547–554
Rowland RG, Mitchell ME, Bihrle P (1987) Indiana continent urinary reservoir. J Urol 137: 1136
Schwaibold H, Klingenberger HJ, Huland H (1994a) Langzeitergebnisse einer intravesikalen Rezidivprophylaxe mit Mitomycin C and Adriamycin bei Patienten mit oberflächlichem Harnblasenkarzinom. Urologe [A] 33: 479–483
Shipley WU, Prout GR Jr, Einstein AB, et al (1987) Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931–935
Stoeckle M, Meyenburg W, Wellek S, et al. (1995) Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153: 47–52
van der Meijden AP, Kurth KH, Oosterlinck W, Debruyne FM (1992) Intravesical therapy with adriamycin and 4epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol 30 (Suppl): S95–S98
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heilmann, HP. (1998). National Differences in the Management of Bladder Cancer. In: Petrovich, Z., Baert, L., Brady, L.W. (eds) Carcinoma of the Bladder. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60258-0_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-60258-0_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64323-1
Online ISBN: 978-3-642-60258-0
eBook Packages: Springer Book Archive